pdf
Published
2021-10-05
Issue
Section
Formulary Evaluations
Categories
License
Copyright (c) 2021 Paul C Langley
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of content published in INNOVATIONS in pharmacy belongs to the author(s).
A Critical Examination of Simulation Pricing and Access Recommendations for Atopic Dermatitis
Paul C. Langley
University of Minnesota
DOI: https://doi.org/10.24926/iip.v12i4.4329
Keywords: atopic dermatitis, ICER, pseudoscience, negative preferences, QoLIAD, PIQoL-AD
Abstract
It has been demonstrated conclusively that value and utility preference scores have only ordinal properties. This means, as has been pointed out on numerous occasions, that the quality adjusted life year (QALY) is a mathematically impossible construct. The implications are profound: Some 30 years of health technology assessment is called into question due to a failure to recognize the well-documented limitations imposed by the axioms of fundamental measurement. The purpose of this commentary is provide a critical examination of this practice in recommendations for atopic dermatitis.
